WALTHAM, Mass. — Thermo Fisher Scientific Inc. reported a 10% increase in second-quarter revenue, as improving customer activity across its end markets helped drive higher earnings and organic growth.
Revenue rose to $11.99 billion for the quarter ended June 27, compared with $10.85 billion in the same period last year. Organic revenue growth was 5%.
GAAP diluted earnings per share increased 9% to $4.68, while adjusted earnings per share rose 13% to $6.03.
“We delivered outstanding performance in the second quarter, reflecting the strength of our proven growth strategy, our team’s excellent execution and the power of our PPI Business System,” said Marc N. Casper, Chairman and Chief Executive Officer of Thermo Fisher Scientific. “Our end markets continue to strengthen and we’re making great progress enhancing our capabilities, and further advancing our trusted partner status with customers, leading to continued share gain.”
Casper said the company remained well positioned for the rest of the year.
“At the halfway point of the year, we are well positioned to deliver a great 2026 and build an even brighter future for our company,” he said.
GAAP operating income increased 14% to $2.09 billion, while the company’s GAAP operating margin improved to 17.4% from 16.9% a year earlier.
Adjusted operating income rose 15% to $2.73 billion. Adjusted operating margin increased to 22.8%, compared with 21.9% in the second quarter of 2025.
During the quarter, Thermo Fisher introduced several new products, including next-generation Orbitrap mass spectrometry platforms equipped with artificial intelligence-driven analytics.
The Thermo Scientific Orbitrap Tribrid Apex Mass Spectrometer is designed to allow researchers to study complex biology across multiomics, structural biology, biopharmaceutical characterization and small-molecule analysis using a single system.
The company also launched the Thermo Scientific Orbitrap Excedion Mass Spectrometer, which is intended to help scientists identify hard-to-detect molecules during drug development, and the Applied Biosystems PowerFlex Thermal Cycler, a next-generation PCR system for molecular biology laboratories.
Thermo Fisher also opened its flagship U.S. Bioprocess Design Center in Plainville, Massachusetts. The facility is part of the company’s global network of collaborative innovation centers serving pharmaceutical and biotechnology customers working to accelerate drug development and optimize manufacturing.
The company announced a strategic collaboration with Precision Health Research, Singapore, to support the PRECISE-SG100K population health study. The collaboration will use Thermo Fisher’s proteomics capabilities, including Olink technology and the Orbitrap Astral mass spectrometry system, to support precision medicine research.
As part of its capital deployment strategy, Thermo Fisher announced the planned divestiture of its microbiology business and repurchased $1 billion of its stock during the quarter.
The company said it would provide updated financial guidance for 2026 during its quarterly earnings conference call.
